Katy Trinkley
Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Decision Support Systems, Clinical | 8 | 2024 | 179 | 4.160 |
Why?
| Pharmacists | 7 | 2019 | 237 | 2.910 |
Why?
| Long QT Syndrome | 4 | 2023 | 59 | 2.170 |
Why?
| Primary Health Care | 9 | 2020 | 1518 | 2.090 |
Why?
| Pharmacy Service, Hospital | 3 | 2019 | 84 | 1.390 |
Why?
| Medical Order Entry Systems | 2 | 2021 | 41 | 1.370 |
Why?
| Irritable Bowel Syndrome | 3 | 2015 | 29 | 1.330 |
Why?
| Lisinopril | 2 | 2020 | 14 | 1.320 |
Why?
| Heart Failure | 6 | 2023 | 1963 | 1.310 |
Why?
| Practice Patterns, Physicians' | 5 | 2020 | 1180 | 1.240 |
Why?
| Hypertension | 4 | 2020 | 1064 | 1.120 |
Why?
| Physicians | 3 | 2023 | 776 | 1.090 |
Why?
| Electronic Health Records | 8 | 2024 | 805 | 0.970 |
Why?
| Constipation | 3 | 2015 | 75 | 0.910 |
Why?
| Interprofessional Relations | 2 | 2015 | 258 | 0.810 |
Why?
| Professional Role | 3 | 2019 | 153 | 0.810 |
Why?
| Losartan | 1 | 2020 | 9 | 0.750 |
Why?
| Angioedema | 1 | 2020 | 17 | 0.730 |
Why?
| Pharmaceutical Services | 2 | 2019 | 79 | 0.710 |
Why?
| Antihypertensive Agents | 2 | 2020 | 432 | 0.690 |
Why?
| Costs and Cost Analysis | 1 | 2020 | 200 | 0.670 |
Why?
| Antipsychotic Agents | 2 | 2018 | 183 | 0.660 |
Why?
| Pharmaceutical Preparations | 1 | 2021 | 169 | 0.650 |
Why?
| Dementia | 2 | 2018 | 185 | 0.630 |
Why?
| Health Personnel | 2 | 2020 | 581 | 0.590 |
Why?
| Electrocardiography | 3 | 2023 | 560 | 0.590 |
Why?
| Pharmacies | 2 | 2019 | 33 | 0.580 |
Why?
| Chronic Pain | 2 | 2019 | 210 | 0.580 |
Why?
| Humans | 41 | 2024 | 115587 | 0.580 |
Why?
| Depression | 4 | 2019 | 1145 | 0.580 |
Why?
| Community Pharmacy Services | 1 | 2017 | 45 | 0.580 |
Why?
| Referral and Consultation | 2 | 2019 | 646 | 0.560 |
Why?
| Program Development | 1 | 2018 | 350 | 0.530 |
Why?
| Analgesics, Opioid | 2 | 2015 | 783 | 0.520 |
Why?
| Nursing Informatics | 1 | 2016 | 26 | 0.520 |
Why?
| Patient Transfer | 1 | 2017 | 143 | 0.520 |
Why?
| Benzodiazepines | 1 | 2016 | 115 | 0.510 |
Why?
| Medication Adherence | 1 | 2020 | 538 | 0.510 |
Why?
| Students, Pharmacy | 1 | 2016 | 100 | 0.500 |
Why?
| Retrospective Studies | 11 | 2023 | 12608 | 0.490 |
Why?
| Cyclohexanols | 1 | 2014 | 9 | 0.490 |
Why?
| Blood Pressure | 2 | 2020 | 1537 | 0.490 |
Why?
| Patient Care Team | 2 | 2016 | 521 | 0.490 |
Why?
| Education, Pharmacy | 1 | 2016 | 128 | 0.480 |
Why?
| Stroke Volume | 3 | 2023 | 509 | 0.480 |
Why?
| Pain Management | 1 | 2017 | 291 | 0.480 |
Why?
| Nurse Practitioners | 1 | 2016 | 105 | 0.470 |
Why?
| Registries | 2 | 2020 | 1770 | 0.470 |
Why?
| Fibromyalgia | 1 | 2014 | 56 | 0.460 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 242 | 0.450 |
Why?
| Torsades de Pointes | 1 | 2013 | 17 | 0.450 |
Why?
| Phentermine | 1 | 2013 | 8 | 0.440 |
Why?
| Telemedicine | 3 | 2020 | 667 | 0.440 |
Why?
| Computer-Assisted Instruction | 1 | 2014 | 64 | 0.440 |
Why?
| Sleep Wake Disorders | 1 | 2016 | 233 | 0.430 |
Why?
| Patient Safety | 1 | 2016 | 276 | 0.430 |
Why?
| Medical Informatics | 1 | 2014 | 93 | 0.430 |
Why?
| Anti-Obesity Agents | 1 | 2013 | 45 | 0.420 |
Why?
| Cooperative Behavior | 1 | 2015 | 390 | 0.420 |
Why?
| Aged | 12 | 2023 | 19251 | 0.420 |
Why?
| Fructose | 1 | 2013 | 100 | 0.420 |
Why?
| Metformin | 1 | 2015 | 278 | 0.400 |
Why?
| User-Computer Interface | 1 | 2013 | 145 | 0.400 |
Why?
| Patient Discharge | 1 | 2017 | 770 | 0.390 |
Why?
| Pharmacogenetics | 2 | 2024 | 151 | 0.380 |
Why?
| Middle Aged | 12 | 2023 | 26999 | 0.370 |
Why?
| Anxiety | 1 | 2016 | 853 | 0.350 |
Why?
| Ambulatory Care | 3 | 2023 | 478 | 0.340 |
Why?
| Focus Groups | 2 | 2023 | 393 | 0.340 |
Why?
| Internet | 1 | 2014 | 602 | 0.330 |
Why?
| Public Health | 1 | 2013 | 438 | 0.310 |
Why?
| Hypoglycemic Agents | 1 | 2015 | 1008 | 0.310 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 1198 | 0.300 |
Why?
| Cross-Sectional Studies | 4 | 2023 | 4435 | 0.290 |
Why?
| Male | 15 | 2020 | 55949 | 0.280 |
Why?
| Cytochrome P-450 CYP2C19 | 2 | 2024 | 24 | 0.280 |
Why?
| Female | 15 | 2020 | 59913 | 0.270 |
Why?
| Delivery of Health Care | 2 | 2024 | 844 | 0.270 |
Why?
| Behavior | 2 | 2019 | 91 | 0.260 |
Why?
| Treatment Outcome | 5 | 2020 | 9159 | 0.240 |
Why?
| Patient Participation | 2 | 2020 | 363 | 0.240 |
Why?
| Pain | 1 | 2010 | 712 | 0.240 |
Why?
| Aged, 80 and over | 4 | 2020 | 6417 | 0.240 |
Why?
| Reproducibility of Results | 2 | 2022 | 2800 | 0.230 |
Why?
| Disease Management | 2 | 2020 | 563 | 0.230 |
Why?
| Program Evaluation | 2 | 2019 | 836 | 0.220 |
Why?
| Prescriptions | 1 | 2023 | 60 | 0.220 |
Why?
| Antidepressive Agents | 2 | 2017 | 195 | 0.210 |
Why?
| Artificial Intelligence | 1 | 2024 | 148 | 0.210 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2015 | 2098 | 0.200 |
Why?
| Dose-Response Relationship, Drug | 2 | 2020 | 1870 | 0.200 |
Why?
| Behavioral Symptoms | 2 | 2018 | 40 | 0.190 |
Why?
| Adult | 7 | 2023 | 30718 | 0.190 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2023 | 301 | 0.180 |
Why?
| Obesity | 1 | 2013 | 2517 | 0.180 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2024 | 399 | 0.180 |
Why?
| Prospective Studies | 3 | 2016 | 6264 | 0.180 |
Why?
| Surveys and Questionnaires | 3 | 2016 | 4665 | 0.180 |
Why?
| Evaluation Studies as Topic | 1 | 2020 | 169 | 0.180 |
Why?
| Risk Factors | 3 | 2023 | 8697 | 0.170 |
Why?
| Grounded Theory | 1 | 2019 | 30 | 0.170 |
Why?
| Sex Factors | 2 | 2015 | 1736 | 0.170 |
Why?
| Biological Specimen Banks | 1 | 2020 | 95 | 0.170 |
Why?
| United States | 4 | 2018 | 12295 | 0.160 |
Why?
| Curriculum | 2 | 2016 | 852 | 0.160 |
Why?
| Drug Administration Schedule | 1 | 2020 | 724 | 0.160 |
Why?
| Evidence-Based Medicine | 2 | 2014 | 684 | 0.150 |
Why?
| Medication Therapy Management | 1 | 2019 | 67 | 0.150 |
Why?
| Residential Facilities | 1 | 2017 | 6 | 0.150 |
Why?
| Models, Organizational | 1 | 2018 | 143 | 0.150 |
Why?
| Independent Living | 1 | 2018 | 84 | 0.140 |
Why?
| Academic Medical Centers | 1 | 2020 | 414 | 0.140 |
Why?
| Medication Errors | 1 | 2017 | 89 | 0.140 |
Why?
| Chronic Disease | 2 | 2020 | 1598 | 0.140 |
Why?
| Precision Medicine | 1 | 2020 | 344 | 0.140 |
Why?
| Intersectoral Collaboration | 1 | 2016 | 56 | 0.130 |
Why?
| Telenursing | 1 | 2016 | 9 | 0.130 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 180 | 0.130 |
Why?
| Laxatives | 1 | 2015 | 17 | 0.130 |
Why?
| Health Care Surveys | 1 | 2017 | 538 | 0.130 |
Why?
| Quality Improvement | 2 | 2020 | 958 | 0.130 |
Why?
| Office Visits | 1 | 2015 | 79 | 0.130 |
Why?
| Perception | 1 | 2017 | 315 | 0.120 |
Why?
| Young Adult | 3 | 2016 | 10470 | 0.120 |
Why?
| Venlafaxine Hydrochloride | 1 | 2014 | 11 | 0.120 |
Why?
| Drugs, Investigational | 1 | 2014 | 30 | 0.120 |
Why?
| Interviews as Topic | 1 | 2016 | 596 | 0.110 |
Why?
| Systems Integration | 1 | 2014 | 38 | 0.110 |
Why?
| PubMed | 1 | 2013 | 11 | 0.110 |
Why?
| Models, Educational | 1 | 2014 | 86 | 0.110 |
Why?
| Drug Combinations | 1 | 2013 | 289 | 0.100 |
Why?
| Adolescent | 3 | 2016 | 17889 | 0.100 |
Why?
| Communication | 1 | 2017 | 750 | 0.100 |
Why?
| Follow-Up Studies | 1 | 2020 | 4440 | 0.100 |
Why?
| Teaching | 1 | 2014 | 224 | 0.100 |
Why?
| Parasympatholytics | 1 | 2010 | 13 | 0.090 |
Why?
| Antidiarrheals | 1 | 2010 | 15 | 0.090 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2010 | 27 | 0.090 |
Why?
| Life Style | 1 | 2013 | 429 | 0.090 |
Why?
| Attitude of Health Personnel | 1 | 2017 | 990 | 0.090 |
Why?
| Dietary Fiber | 1 | 2010 | 40 | 0.090 |
Why?
| Diarrhea | 1 | 2010 | 173 | 0.080 |
Why?
| Abdominal Pain | 1 | 2010 | 135 | 0.080 |
Why?
| Cohort Studies | 1 | 2019 | 4944 | 0.080 |
Why?
| Clinical Competence | 1 | 2016 | 912 | 0.080 |
Why?
| Colorado | 2 | 2020 | 4113 | 0.080 |
Why?
| Age Factors | 1 | 2015 | 2907 | 0.080 |
Why?
| Dietary Supplements | 1 | 2010 | 458 | 0.070 |
Why?
| Drug Overdose | 1 | 2010 | 296 | 0.070 |
Why?
| Cluster Analysis | 1 | 2022 | 465 | 0.050 |
Why?
| Health Services Misuse | 1 | 2020 | 36 | 0.040 |
Why?
| Quality of Life | 1 | 2010 | 2385 | 0.040 |
Why?
| Machine Learning | 1 | 2022 | 321 | 0.040 |
Why?
| Genotype | 1 | 2024 | 1786 | 0.040 |
Why?
| Child | 1 | 2016 | 18488 | 0.040 |
Why?
| Long-Term Care | 1 | 2017 | 76 | 0.040 |
Why?
| Ventricular Dysfunction, Left | 1 | 2020 | 366 | 0.030 |
Why?
| Physician-Patient Relations | 1 | 2020 | 465 | 0.030 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2020 | 1216 | 0.030 |
Why?
| Cardiovascular Diseases | 1 | 2024 | 1724 | 0.030 |
Why?
|
|
Trinkley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|